Do elevated DEHP metabolites indicate phthalate exposure and disrupted male hormone signaling?

Di(2-ethylhexyl) phthalate (DEHP) is a widespread environmental plasticizer known to alter endocrine function. Tracking its intake and understanding its physiological impacts are vital for assessing male reproductive health.

Biomarkers of exposure

• Excretory kinetics: DEHP is rapidly metabolized in the body, hydrolyzing into mono-2-ethylhexyl phthalate (MEHP), which is further oxidized into mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP) and mono-2-ethyl-5-oxohexyl phthalate (MEOHP).
• Clinical utility: Because these metabolites have short half-lives of 4 to 10 hours and more than 90% of a dose is excreted within 24 hours, they serve as sensitive biomarkers of recent exposure.
• Measurement reliability: The oxidative metabolites MEHHP and MEOHP are highly correlated in urine ($r = 0.928$ to $0.98$) and provide a reliable, contamination-free measure of internal DEHP dose compared to MEHP alone.

Mechanistic disruption of steroidogenesis

• Leydig cell toxicity: Phthalates directly target testicular Leydig cells to impair androgen synthesis.
• Molecular pathways: The active metabolite MEHP inhibits luteinizing hormone (LH) receptor-stimulated cAMP signaling and downregulates the expression of steroidogenic acute regulatory (StAR) protein, which is required for mitochondrial cholesterol transport.
• Enzymatic suppression: Phthalates downregulate key steroidogenic enzymes, including Cyp11a1 and 3β-HSD, leading to a substantial decrease in testosterone production.

Impact on the HPG axis

• Feedback loop alteration: The decline in circulating testosterone reduces the normal negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.
• Gonadotropin drive: This loss of feedback triggers a compensatory increase in pituitary gonadotropin drive, resulting in elevated serum LH levels, altered testosterone-to-LH ratios, and Leydig cell hyperplasia.

Bottom line

• Elevated urinary levels of MEHP, MEHHP, and MEOHP are validated indicators of recent DEHP exposure, which disrupts male endocrine function by directly impairing Leydig cell steroidogenesis to lower testosterone levels, thereby triggering a compensatory increase in pituitary gonadotropin drive.